TABLE 1

FDA-approved formulations for the treatment of chronic hepatitis Ca

Generic name(s) (concn [mg])AbbreviationU.S. brand nameDosingIndication(s)
Daclatasvir (60)DCVDaklinzaOne tablet taken once dailyApproved for treatment of GT1 or GT3 infection when used with sofosbuvir, +/− ribavirin, for 12 wk
Elbasvir (50)-grazoprevir (100)EBR-GZRZepatierOne tablet taken once dailyApproved for treatment of GT1 or GT4 infection, +/− ribavirin, for 12-wk duration or for 16-wk duration for GT1a infection, treatment-experienced patients with NS5A resistance-associated variants, and GT4-infection treatment-experienced patients
Ledipasvir (90)-sofosbuvir (400)LDV-SOFHarvoniOne tablet taken once dailyApproved for treatment of GT1, GT4, GT5, and GT6 infection, +/− ribavirin, for 12 wk, or for 24 wk for patients with GT1a infection with compensated cirrhosis
Ombitasvir (12.5)-paritaprevir (75)PrOTechnivieTwo ombitasvir-paritaprevir-ritonavir tablets taken once daily (morning)Approved for treatment of GT4, +/− ribavirin, for 12 wk, including patients with compensated cirrhosis
Ombitasvir (12.5)-paritaprevir (75)-ritonavir (50) + dasabuvir (250)PrODViekira PakTwo ombitasvir-paritaprevir-ritonavir tablets taken once daily (morning), one dasabuvir tablet taken twice dailyApproved for treatment of GT1b infection, and GT1a infection when used with ribavirin, for 12 wk; for patients with GT1a infection and compensated cirrhosis, treatment should be extended to 24 wk
Ombitasvir (8.33)-paritaprevir (50)-dasabuvir (200)-ritonavir (33.33)PrODViekira XRThree fixed-dose combination tablets once dailyApproved for treatment of GT1b infection, and GT1a infection when used with ribavirin, for 12 wk; for patients with GT1a infection and compensated cirrhosis, treatment should be extended to 24 wk
Simeprevir (150)SMVOlysioOne capsule taken once dailyApproved for treatment of GT1 infection when used with sofosbuvir for 12-wk duration
Sofosbuvir (400)SOFSovaldiOne tablet taken once dailyApproved for treatment of GT1, GT2, GT3, or GT4 infection when combined with other antiviral medications.
Sofosbuvir (400)-velpatasvir (100)SOF-VELEpclusaOne tablet taken once dailyApproved for treatment of GT1, GT2, GT3, GT4, GT5, or GT6 infection, with or without cirrhosis (compensated), for 12 wk; for those with advanced cirrhosis (decompensated), approved for use with ribavirin for 12 wk
  • a Shown are IFN-free treatment regimens for chronic hepatitis C currently approved by the FDA as of July 2016. GT, genotype.